Treace John T.'s Form 4 filing
Treace Medical Concepts, Inc. (TMCI) · filed Aug 24, 2026
- Accession no.
- 0001193125-26-363737
- Filed
- Aug 24, 2026, 5:00 PM ET
- Trade date
- Aug 20-24, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market purchases total $246.7K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Treace John T.CIK 0001856380 | Director, Officer (Chief Executive Officer), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 20, 2026 | Common Stock | PPurchaseAcquired | +39,944 | $4.44F1 | +$177,175.61 | 7,388,383 | Direct | |
| Aug 21, 2026 | Common Stock | PPurchaseAcquired | +5,000 | $4.35 | +$21,747.5 | 7,393,383 | Direct | |
| Aug 24, 2026 | Common Stock | PPurchaseAcquired | +11,000 | $4.34F3 | +$47,731.2 | 7,404,383 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $4.3198 to $4.5048 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $4.3097 to $4.3489 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.